Cancer Metastasis Prediction Statistics 2026 | AI, 80% Accuracy & Facts

Cancer Metastasis Prediction in 2026: When AI Learns What Biology Has Struggled to Explain

For decades, one of the most frustrating realities in oncology has been that two patients can receive the same cancer diagnosis, at the same stage, with the same tumor size — and one will go on to develop distant metastases within two years while the other will remain disease-free for life. Nobody could predict which patient was which. Not the pathologist reviewing the biopsy slides. Not the oncologist examining the imaging. Not the genomics lab sequencing the tumor’s mutations. Metastasis — the process by which cancer cells break away from the original tumor and establish new colonies in distant organs — is the primary reason why cancer kills more than 10.4 million people globally every year, and until recently, its prediction remained one of medicine’s most stubborn unsolved problems.

What is changing that in 2026 is artificial intelligence applied to molecular biology at a resolution that was simply unavailable even five years ago. In January 2026, a team at the University of Geneva published a landmark study in the peer-reviewed journal Cell Reports, describing an AI model called MangroveGS (Mangrove Gene Signatures) that can predict whether colon cancer will metastasize or recur with nearly 80% accuracy — a performance that outstrips every existing prediction tool and, crucially, extends its predictive power to breast, lung, and stomach cancers from the same gene signatures. This headline number — 80% accuracy — sits inside a broader transformation of how AI is being applied to metastasis detection, from deep learning models reading lymph node involvement in MRI and CT scans to multimodal machine learning combining genomic data with clinical records. The 2026 statistics across all of these approaches tell a story of genuine, clinically meaningful progress in one of oncology’s hardest problems.

Interesting Facts 2026: Cancer Metastasis & AI Prediction at a Glance

CANCER METASTASIS — The Scale of the Problem (2026)
====================================================

  Global Cancer Deaths (2023)     ████████████████████████████████████████  10.4 million/year
  US Cancer Deaths (projected '26)████████████████████████████████████████  626,140
  US New Cases (projected 2026)   ████████████████████████████████████████  2,114,850
  Metastasis Share of Cancer Death████████████████████████████████████████  ~90% of all deaths

  5-YEAR SURVIVAL RATE — Stage vs. Stage
  Localized (all cancers, 2015-21) ████████████████████████████████████████  91%
  Regional Stage                   ████████████████████████████████████      69%
  Distant/Metastatic Stage         ████████████████                          35% (up from 17%)

  AI PREDICTION ACCURACY — Key Studies (2026)
  MangroveGS (colon cancer, UNIGE) ████████████████████████████████████████  ~80% accuracy
  Deep Learning (breast LN, JMIR)  ████████████████████████████████████████  AUC 0.89
  AI Radiology (metastasis, pooled)████████████████████████████████████████  AUC 0.90
  Colorectal LN (DL vs radiologist)████████████████████████████████████████  89% sensitivity, AUC 0.93
  Gastric CT + adipose AI model    ████████████████████████████████████████  AUC 0.86

Sources: American Cancer Society Cancer Statistics 2026 (PMC, NIH), UNIGE/Cell Reports 2026, JMIR (Jan 2026), eClinicalMedicine (Lancet), Frontiers in Cell and Developmental Biology (2026), Diagnostic Imaging Oct 2025, Global Burden of Disease Study 2023 (The Lancet, Sept 2025), CureToday, theworlddata.com — May 2026

The sheer scale of the metastasis problem is worth sitting with before moving to the solutions. When approximately 90% of all cancer deaths are attributable to metastasis rather than the original localized tumor, every percentage point of improvement in metastasis prediction becomes a lever on the most consequential outcome in cancer medicine. The 35% five-year survival rate for distant-stage disease, while it represents genuine progress from the 17% recorded in the mid-1990s, still means that 65 out of every 100 Americans diagnosed with metastatic cancer today will not survive five years. That gap — between 91% localized survival and 35% distant survival — quantifies precisely why catching cancer before it spreads, or predicting with accuracy which tumors are most likely to spread, is among the most valuable clinical problems AI can address.

The 2026 AI accuracy statistics represent a meaningful inflection point in this effort. The MangroveGS model’s ~80% accuracy in predicting colon cancer metastasis and recurrence is the headline, but it exists alongside a rich body of evidence from independent research groups, imaging modalities, and cancer types. A pooled meta-analysis of 34 radiology AI studies found a collective AUC of 0.90 — close to perfect discrimination — for detecting tumor metastasis from medical imaging. A separate JMIR 2026 meta-analysis analyzing 28 deep learning studies covering 20,811 breast cancer patients found pooled sensitivity of 0.80 and AUC of 0.89 for axillary lymph node metastasis detection. And in October 2025, a direct comparison showed deep learning models detecting colorectal cancer lymph node metastasis at 89% sensitivity and AUC 0.93, compared to 65% sensitivity and AUC 0.76 for unassisted radiologists. The field is not converging on a single breakthrough — it is generating breakthroughs across multiple cancer types simultaneously.

MangroveGS AI Model Statistics 2026 | The 80% Accuracy Breakthrough in Detail

MANGROVES AI MODEL — How It Works & What It Achieves
=====================================================

  Input: RNA sequencing from hospital tumor samples
         └── Hundreds of gene expression signatures analyzed
         └── Focuses on GROUPS of related cancer cells, not single mutations
         └── Gene expression GRADIENTS linked to migratory potential

  Training Data: ~30 clones from 2 primary colon tumors
                 └── In vitro testing + mouse model validation

  Output: Metastasis Risk Score
          └── Transmitted via encrypted Mangrove portal
          └── Accessible to oncologists and patients

  PERFORMANCE:
  Colon Cancer Metastasis Prediction:  ████████████████████████████████████  ~80% accuracy ★
  Existing Tools (comparison):         █████████████████████                 Significantly lower ★

  CROSS-CANCER APPLICABILITY:
  Breast Cancer        ✓ Predictive
  Lung Cancer          ✓ Predictive
  Stomach Cancer       ✓ Predictive
  Colon Cancer         ✓ Primary training cancer

  ★ Performance described by UNIGE as "far superior to existing tools"

Sources: UNIGE official press release (unige.ch/medias/en, Jan 2026), ScienceDaily (March 21, 2026), medicalxpress.com (Jan 22, 2026), biotecnika.org (March 2026), wutshot.com, tun.com — May 2026

The MangroveGS model’s core intellectual contribution is not just its accuracy — it is the biological reframing that makes that accuracy possible. Every prior effort to predict cancer metastasis had focused primarily on identifying the single genetic mutation or single molecular marker that explained why a cell migrated. These approaches consistently fell short, because no single genetic alteration has ever reliably explained metastatic behavior across patients. The Geneva team’s discovery was that metastatic potential is not encoded in any one gene but emerges from the coordinated, collective behavior of gene activity gradients across groups of related cancer cells. By training MangroveGS on hundreds of gene signatures simultaneously rather than hunting for a single predictive biomarker, the model becomes robust to the individual patient variation that makes single-marker approaches unreliable. The fact that signatures derived from colon cancer predict metastatic risk in breast, lung, and stomach cancers strongly suggests the team has identified something close to a universal biological mechanism underlying how cancer decides to spread.

The clinical pipeline MangroveGS enables is also practically significant. The tool requires only a standard hospital tumour biopsy sample — not an expensive, specialized test requiring rare facilities. The RNA sequencing can be performed locally at the hospital, and the anonymised data is processed through a secure encrypted portal that returns a metastasis risk score to both the oncologist and the patient. This design means the barrier to clinical deployment, once validated in larger cohorts, is substantially lower than tools that require specialized imaging equipment, proprietary reagents, or centralized laboratory processing. The researchers explicitly designed it for real-world hospital integration, not just academic use — a distinction that separates MangroveGS from many AI models that perform brilliantly in controlled trials but struggle to reach patients.

AI Deep Learning Metastasis Detection Statistics 2026 | Radiology & Imaging

AI vs. RADIOLOGIST — Metastasis Detection Performance (2026)
=============================================================

  COLORECTAL LYMPH NODE DETECTION (MRI-based DL vs. Radiologist, Oct 2025):
  Deep Learning sensitivity:    ████████████████████████████████████████████  89%
  Radiologist sensitivity:      ████████████████████████████                  65%

  Deep Learning AUC:            ████████████████████████████████████████████  0.93
  Radiologist AUC:              ████████████████████████████████              0.76

  BREAST CANCER ALN DETECTION (28 studies, 20,811 patients, JMIR 2026):
  DL Pooled Sensitivity:        ████████████████████████████████████████      0.80
  DL Pooled Specificity:        ████████████████████████████████████████████  0.85
  DL Pooled AUC:                ████████████████████████████████████████████  0.89

  AI RADIOLOGY POOLED META-ANALYSIS (69 studies, eClinicalMedicine):
  Pooled Sensitivity:           ████████████████████████████████████████████  82% (95% CI: 79–84%)
  Pooled Specificity:           ████████████████████████████████████████████  84% (82–87%)
  Pooled AUC:                   ████████████████████████████████████████████  0.90 (0.87–0.92)
  Machine Learning Sensitivity: ████████████████████████████████████████████  87%
  Deep Learning Sensitivity:    ████████████████████████████████████████████  86%

Sources: JMIR (jmir.org/2026/1/e77593), eClinicalMedicine (Lancet/PMC), Diagnostic Imaging (Oct 2025), cancerimagingjournal.biomedcentral.com (March 2025), PMC/ncbi (colorectal LN meta-analysis Nov 2025), PMC/ncbi (YOLO-v11, March 2026), ocacademy.in (gastric cancer AI), Frontiers in Cell and Developmental Biology (2026), PMC/ncbi (PCMM-Net) — May 2026

The side-by-side comparison of deep learning and unassisted radiologists in detecting colorectal cancer lymph node metastasis — 89% sensitivity and AUC 0.93 for AI versus 65% sensitivity and AUC 0.76 for radiologists — is one of the most consequential performance gaps in modern diagnostic medicine. A 24-percentage-point sensitivity advantage means that, for every 100 patients with lymph node metastasis, AI correctly identifies approximately 24 additional patients that the radiologist reading alone would miss. In the context of cancer staging — where a missed lymph node call can mean the difference between a curative surgical plan and an inadequate one — each of those 24 patients represents a potentially life-altering clinical error avoided. The pooled AUC of 0.90 from the eClinicalMedicine meta-analysis spanning 69 studies confirms that this level of performance is not a single-study anomaly. Across different cancer types, imaging modalities (CT, MRI, PET/CT, ultrasound), AI architecture choices (CNN, machine learning, deep learning), and patient populations, the directional consistency is clear: AI for radiological metastasis detection consistently matches or outperforms experienced radiologists by statistically significant margins.

The gastric cancer CT + adipose tissue AI model’s AUC of 0.86 deserves particular clinical attention because it addresses a historically difficult diagnostic challenge. Peritoneal metastasis in serosa-invasive gastric cancer — cancer spread to the abdominal lining — is notoriously difficult to detect preoperatively by conventional means. Many patients are deemed operable based on standard imaging and staging, only for surgeons to discover peritoneal spread during the procedure. The AI model, using a ResNet18 network to extract features from both the tumor and the surrounding visceral fat tissue, catches these cases that clinical models routinely miss. The YOLO-v11 object detection model applied to breast ultrasound images achieved a mAP@0.5 of 0.904 across 471 patients — a precision-recall metric indicating it correctly localizes both benign and malignant lymph nodes with greater than 90% reliability. These are not experimental curiosities; they are detection-grade tools built on architectures that have already proven themselves in computer vision tasks at industrial scale.

US Cancer Metastasis Survival Statistics 2026 | The Clinical Stakes

US CANCER SURVIVAL BY STAGE — Historical Progress (Mid-1990s → 2015–2021)
==========================================================================

  ALL CANCERS 5-YEAR SURVIVAL:
  Mid-1990s     ████████████████████████████████████████████████████  63%
  2015–2021     ████████████████████████████████████████████████████████████  70% ★ ALL-TIME RECORD

  REGIONAL STAGE:
  Mid-1990s     ████████████████████████████████████████████████████  54%
  2015–2021     ████████████████████████████████████████████████████████████████  69%

  DISTANT/METASTATIC STAGE:
  Mid-1990s     ████████████  17%
  2015–2021     ████████████████████████████████████  35% (+18 points; survival more than DOUBLED)

  CANCER TYPE — Metastatic Stage 5-Year Survival Improvements:
  Metastatic Melanoma  Mid-1990s: 16% → Now: 35%  (+19 points)
  Regional Lung Cancer Mid-1990s: 20% → Now: 37%  (+17 points)
  Metastatic Lung      Mid-1990s:  2% → Now: 10%  (+8 points)
  Metastatic Rectal    Mid-1990s:  8% → Now: 18%  (+10 points)
  Myeloma              Mid-1990s:  7% → Now: 22%  (+15 points)
  Liver Cancer         Mid-1990s: 16% → Now: 35%  (+19 points)

Sources: American Cancer Society Cancer Statistics 2026 (PMC/NIH, pmc.ncbi.nlm.nih.gov/articles/PMC12798275), CURE Today (curetoday.com, May 2026), theworlddata.com (March 2026), PMC future metastatic cancer trends study — May 2026

The doubling of metastatic cancer survival from 17% to 35% since the mid-1990s is one of the most important public health achievements of the last three decades — and it has been almost entirely driven by new therapeutic modalities rather than improved prediction. As the American Cancer Society’s chief scientific officer William Dahut stated explicitly in January 2026: this progress was “really driven by new therapies” — particularly immunotherapies, targeted molecular drugs, and PD-1/PD-L1 checkpoint inhibitors that became widely available starting in the 2010s. The metastatic melanoma story is the most dramatic illustration: from 16% five-year survival in the mid-1990s to 35% today — a condition that was essentially a death sentence within a year of diagnosis has, for many patients, become a manageable chronic disease. Metastatic lung cancer’s improvement from 2% to 10% is smaller in absolute terms but represents a fivefold increase in a cancer that still causes more US deaths than colorectal and pancreatic cancer combined.

What AI-based metastasis prediction tools like MangroveGS add to this therapeutic progress is a capability that better treatments alone cannot provide: knowing earlier, and with greater precision, which patients need the aggressive treatment. Even the best immunotherapy carries significant toxicity, cost, and quality-of-life impact. A patient with genuinely low metastatic risk does not benefit from aggressive systemic therapy — they are harmed by it. Conversely, a patient whose tumor has a high predicted metastatic score but whose imaging is currently clear may need surveillance imaging every 3 months instead of every 6, or an earlier conversation about adjuvant chemotherapy. The 46.7% greater odds of long-term metastatic survivorship projected for 2040 assumes continued improvement in both therapies and early detection — but that projection depends heavily on the kind of predictive intelligence that AI is now beginning to provide.

AI Metastasis Prediction by Cancer Type 2026 | Colon, Breast, Lung & Beyond

AI METASTASIS PREDICTION ACCURACY — By Cancer Type (2026)
==========================================================

  Colorectal LN (DL, MRI, Oct 2025)  ████████████████████████████████████████  AUC 0.93
  Colorectal LN (pooled, Nov 2025)    ████████████████████████████████████████  AUC 0.88
  Deepath-MSI (CRC, NMPA-approved)    ████████████████████████████████████████  AUROC 0.98

  Colon Metastasis (MangroveGS)       ████████████████████████████████████████  ~80% accuracy

  Breast ALN (DL, JMIR 2026)         ████████████████████████████████████████  AUC 0.89
  Breast ALN (YOLO-v11 ultrasound)   ████████████████████████████████████████  mAP 0.904
  Breast LVI (PCMM-Net, 2026)        ████████████████████████████████████████  AUC 0.843

  Gastric peritoneal (CT AI)          ████████████████████████████████████████  AUC 0.86

  Lung adenocarcinoma (CT AI, 2025)   ████████████████████████████████████████  AUC 0.936 (IAC)
  Prostate (PET/CT CNN)               ████████████████████████████████████████  Outperforms CAD

Sources: JMIR (jmir.org/2026/1/e77593), Diagnostic Imaging (Oct 2025), PMC/Medicine (Nov 2025), Cell Reports/UNIGE (Jan 2026), eClinicalMedicine, Cancer Imaging Journal (March 2025), Frontiers in Cell and Developmental Biology (2026), PMC (YOLO-v11, March 2026) — May 2026

The cancer-type breakdown of AI metastasis prediction accuracy reveals a consistent pattern: wherever researchers have applied rigorous deep learning models to well-curated imaging datasets, the performance exceeds what conventional clinical staging achieves. Colorectal cancer has emerged as the frontrunner in AI-assisted metastasis staging, with the NMPA-approved Deepath-MSI device at AUROC 0.98 representing something rare: an AI oncology tool that has completed the full journey from algorithm to regulatory-approved clinical device. The Colorectal LN meta-analysis of November 2025 — covering 12 studies and 8,540 patients — provides the statistical robustness needed to confirm that the individual study results are not flukes. Breast cancer sits close behind, with the JMIR 2026 meta-analysis drawing on 20,811 patients across 28 deep learning studies producing AUC 0.89 — and the YOLO-v11 ultrasound model at mAP 0.904 showing that even relatively accessible, widely available ultrasound imaging can serve as a substrate for high-accuracy AI lymph node assessment.

Lung cancer presents a different challenge and a different type of AI opportunity. The CT radiomic deep learning model achieving AUC 0.936 for invasive adenocarcinoma subtyping is not predicting metastasis directly — it is distinguishing tumor subtypes that carry different metastatic risk profiles. This distinction matters clinically: a minimally invasive adenocarcinoma (MIA) and an invasive adenocarcinoma (IAC) on a CT scan can look nearly identical to the human eye, yet they carry dramatically different probability of nodal spread and distant metastasis. The model’s ability to separate them at AUC 0.936 could directly inform whether a patient receives surveillance, wedge resection, or lobectomy — a decision with enormous quality-of-life consequences. The noted “gray zone” for MIA at AUC 0.707 indicates that even the best current models have blind spots, and that combining CT radiomic features with longitudinal data and clinical context remains an important next step for the field.

AI Cancer Prediction Technology Statistics 2026 | Genomics, Liquid Biopsy & Multimodal Models

EMERGING AI METASTASIS PREDICTION PLATFORMS — 2026
====================================================

  GENOMIC / GENE EXPRESSION AI:
  MangroveGS (UNIGE)    RNA sequencing → ~80% metastasis accuracy (colon, + 3 cancer types)
  Precision Oncology    Multi-omic AI: genomic + spatial pathology + radiomic data combined

  LIQUID BIOPSY + AI:
  ctDNA detection       Identifies relapse in 93% of cases, median 70 days pre-radiologic confirmation
  AI-enhanced ctDNA     Improved signal detection → earlier, more precise recurrence prediction
  Multi-cancer liquid biopsy → blood test covering 50+ cancer types (MCED platforms in clinical trials)

  MULTIMODAL ML (Swedish multi-cancer cohort, arXiv 2026):
  Data integrated:      Clinical records + genomics + pathology imaging
  Coverage:             Multiple cancer types, metastasis prediction before clinical detection

  RADIOLOGY AI:
  PET/CT CNN            Whole-body: bone, lung, liver, lymph node metastasis in single scan
  MRI DL (colorectal)   89% sensitivity, AUC 0.93 — outperforms radiologist by 24 sensitivity points
  CT radiomic (lung)    AUC 0.936 for invasive vs. non-invasive adenocarcinoma

  PATHOLOGY AI:
  Deepath-MSI (CRC)     AUROC 0.98 — regulatory-approved Class III device (China NMPA, 2025)
  Digital pathology DL  Automated AML molecular aberration diagnosis — cellular to molecular classification

Sources: PMC (ctDNA liquid biopsy reviews, 2026), PMC (Frontiers Cell & Dev Biology, 2026), arXiv multimodal ML (2026), AACR 2025 liquid biopsy highlights, PMC (AI in Radiology 2025), PMC (Metastatic Cancer Detection with AI and AR, Jan-Feb 2026), Diagnostic Imaging (Oct 2025), PMC (AML DL flow cytometry) — May 2026

The convergence of genomics, imaging, and liquid biopsy under AI-driven multimodal frameworks is the defining technological trajectory for cancer metastasis prediction in 2026. Where the first generation of oncology AI tools took a single modality — an MRI, a CT scan, a genomic panel — and tried to extract maximum predictive value from it alone, the current generation is learning to combine signals across data types that no human clinician could synthesize simultaneously. The Swedish multi-cancer cohort multimodal ML study (arXiv, 2026) integrating clinical records, genomic data, and pathology imaging across multiple cancer types represents this direction most explicitly. The practical impact of this approach is that it can identify metastatic risk signals in combination patterns that individually appear benign — a principle directly analogous to how MangroveGS uses hundreds of gene signatures simultaneously rather than any single marker.

The ctDNA liquid biopsy statistics capture a complementary prediction modality that AI is dramatically enhancing. The landmark finding that ctDNA analysis correctly predicts relapse in 93% of cases, with a median lead time of 70 days before radiologic confirmation, means that for nearly every patient who will relapse, liquid biopsy with AI analysis can know it is coming more than two months before any imaging scan can see it. Those 70 days represent an enormous clinical window — enough time to initiate salvage chemotherapy, enroll in a clinical trial, reassess surgical options, or intensify surveillance before measurable distant disease has established itself. AI-enhanced signal detection at low tumour fractions addresses one of liquid biopsy’s longstanding limitations: early-stage cancers shed very little DNA into the bloodstream, making signal-to-noise separation technically challenging. Machine learning algorithms trained on large ctDNA datasets are now achieving the sensitivity at low tumour fractions that makes liquid biopsy clinically actionable well before the disease becomes radiologically visible.

Important note for readers: This article covers research and statistical data about cancer metastasis prediction. If you or someone you know is facing a cancer diagnosis or concerned about metastatic risk, please speak directly with a qualified oncologist or healthcare professional. Published AI prediction statistics represent research findings and population-level data — they are not a substitute for individualized clinical assessment.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE